Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immutep ( (IMMP) ) just unveiled an announcement.
On December 8, 2025, Immutep Limited announced a strategic collaboration with Dr. Reddy’s Laboratories for the commercialization of its innovative oncology drug, Eftilagimod Alfa (efti), outside North America, Europe, Japan, and Greater China. This agreement grants Dr. Reddy’s exclusive rights to develop and commercialize efti in these regions, with Immutep receiving an upfront payment of USD 20 million and potential milestone payments of up to USD 349.5 million, along with double-digit royalties on sales. The partnership is expected to enhance Immutep’s market presence and validate the potential of efti, which is currently under evaluation in a Phase III trial for non-small cell lung cancer and other cancer types.
The most recent analyst rating on (IMMP) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative cash flows. While technical indicators suggest some positive momentum, the valuation remains unattractive due to a negative P/E ratio and lack of dividends. These factors collectively result in a below-average stock score.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company specializing in the development of novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and advancement of Lymphocyte Activation Gene-3 (LAG-3) related therapeutics, aiming to harness LAG-3’s potential to either stimulate or suppress the immune response.
Average Trading Volume: 601,196
Technical Sentiment Signal: Buy
Current Market Cap: $253.9M
For a thorough assessment of IMMP stock, go to TipRanks’ Stock Analysis page.